Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXPRE: Dexmedetomidine vs Midazolam Sedation in Preterm Infants
NCT06878703Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine in sedation (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time from discontinuation of experimental treatment to extubation up to 48 hours. Started Oct 2025; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
sedation
Beyond the preview
Go deeper on NCT06878703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878703.